1,755 filings
Page 16 of 88
6-K
kjjwcoghjykvmh
26 Apr 17
Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer
12:00am
6-K
gguo f4dnmco
26 Apr 17
Teva Announces Launch of Generic Vytorin® In the United States
12:00am
6-K
n6tiusrg 5otjl
20 Apr 17
Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol
12:00am
6-K
1zz mrij2v22rdm
19 Apr 17
Teva Showcases CNS Portfolio at 69thAnnual Meeting of the American Academy of Neurology
12:00am
6-K
vcch28 zk
13 Apr 17
Teva Provides Update on API China Manufacturing Facility
12:00am
6-K
tw78ssqu4k3
6 Apr 17
Live Filing
12:00am
6-K
nm58kx5wtmgk9w82 wb6
3 Apr 17
Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
12:00am
6-K
ux1t wo1y
16 Mar 17
Live Filing
12:00am
6-K
y9hnjejctquunixq9nl
13 Mar 17
Teva to Present at the Barclays GlobalAnnual Healthcare Conference
12:00am
6-K
zk42i9qews
6 Mar 17
Teva to Present at theCowen & Company 37th Annual Healthcare Conference
12:00am
6-K
c1yz37tbpkbt6uqn
1 Mar 17
Teva Announces Launch of Generic Pristiq® In the United States
12:00am
6-K
ofatpvr 7ea0m1ar9h
28 Feb 17
Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia
12:00am
6-K
lyjd3et6 rxmx56d
16 Feb 17
Teva Files 2016 Annual Report on Form 20-F
12:00am
SC 13G/A
ttsc r5pg4le2lzuid7
14 Feb 17
Teva Pharmaceutical Industries LTD
12:00am
6-K
m1m0evo1tlki41lgi67b
13 Feb 17
Teva Reports Full Year and Fourth Quarter 2016 Financial Results
12:00am
6-K
t7mxy
6 Feb 17
Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman
12:00am
6-K
r87fj7
2 Feb 17
Teva Confirms Generic Victoza®patent Challenge In the United States
12:00am
6-K
pkbhgbmmm5p70d20
1 Feb 17
Live Filing
12:00am
6-K
9gvcx1v5y
31 Jan 17
Teva Confirms District Court Decision in COPAXONE® 40 mg/mL Patent Trial
12:00am